Quick takes: ECDC urges fall COVID boosters for risk groups, EUA for new monoclonal antibody, human trial results for Gilead COVID antiviral
The ECDC said though no clear seasonal circulation pattern has emerged, COVID's impact has been higher in the fall and winter.